Clinical Trial Update: Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating three antidiarrheal strategies in HER2-positive, HR-positive early breast cancer patients treated with extended adjuvant neratin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Nerlynx (neratinib)

Snippet

Sponsor: Spanish Breast Cancer Research Group | Conditions: Early-stage Breast Cancer, HER2 Positive Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING